Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MARKET PULSE-McDonald's, Crocs, Amicus, Urban Outfitters, Pep Boys

Tue, 10th Sep 2013 13:16

(For more market insights, including options activity, click on ; for the Day Ahead newsletter http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s)

Sept. 10 (Reuters) - Some U.S. stocks to watch on Tuesday:

FUTURES CLIMB ON ROSY CHINA DATA, EASING SYRIA FEARS

U.S. stock index futures rose, putting the S&P 500 on trackfor a sixth day of gains, following another batch of rosyeconomic data out of China and as expectations eased about aWestern military strike against Syria. S&P 500 futures rose 10.4 points, Dow Jones industrial average futures gained 88 points, and Nasdaq 100 futures added 21points.

** APPLE INC, Monday close $506.17, up 0.5 pctpremarket

Apple is expected to introduce a cheaper version of theiPhone on Tuesday, bringing one of the industry's costliestsmartphones within reach of the masses in poorer emergingmarkets.

** MCDONALD'S CORP, Monday close $96.45, up 1 pctpremarket

The fast food chain reported a better-than-expected 1.9percent increase in global sales at established restaurants inAugust, helped by stronger sales in Europe.

** GOLDMAN SACHS GROUP INC, Monday close $159.49, up2.7 pct premarket

** VISA INC, Monday close $178.55, up 2.5 pctpremarket

** NIKE INC, Monday close $65.40, up 2.3 pctpremarket

** ALCOA INC, Monday close $8.08, down 1.2 pctpremarket

** BANK OF AMERICA CORP, Monday close $14.48

** HEWLETT-PACKARD CO, Monday close $22.36, down 1.3pct premarket

Goldman Sachs, Visa and Nike will replace Alcoa,Bank of America and Hewlett-Packard as components of the DowJones Industrial Average, effective Sept. 23.

** AMICUS THERAPEUTICS, Monday close $2.55, up 20pct premarket

The biotechnology company said it has entered into acollaboration with Biogen Idec to develop andcommercialize novel small molecules for the treatment ofParkinson's disease. The collaboration includes funding byBiogen.

** CHEMOCENTRYX INC, Monday close $8.26, down 19pct premarket

The biopharmaceutical company said its experimental drug fortreating a diabetic kidney disease reduced the level of proteinin the urine, a sign of kidney damage. Interim data from amid-stage trial of the drug, CCX140, showed patients getting 5mg doses for two weeks had a 12 percent reduction in urineprotein levels.

Investment website SeekingAlpha.com said investors mighthave been expecting a reduction of 20 percent or more.

** URBAN OUTFITTERS INC, Monday close $42.71, down8 pct after market

The teen apparel chain said in a regulatory filing on Mondaythat percentage growth in its same-store net sales, includingonline sales, was trending in the mid-single digit in thecurrent quarter. This forecast missed analysts' estimates.Janney Capital Markets analyst Adrienne Tennant cut the pricetarget on the stock to $46 from $52, saying she expected the 9percent growth of the second quarter to continue into thisquarter.

** CYTORI THERAPEUTICS INC, Monday close $2.39, up7 pct premarket

Roth Capital Partners reinstated its "buy" rating on themedical device maker's stock with a $10 price target, sayingpositive data from the trials on Cytori's cell therapy forchronic ischemic heart failure would boost its U.S. profile.

** CROCS INC, Monday close $13.61, down 5 pctpremarket

The maker of colorful clogs cut its revenue and profitforecasts for the quarter ending Sept. 30, citing weakness inits Americas business.

** PEP BOYS-MANNY MOE AND JACK, Monday close $11.52,down 4 pct premarket

The auto repair chain reported a lower-than-expected profitfor the second quarter as tire sales fell.

** MODEL N INC, Monday close $14.73, down 38 pctpremarket

The revenue management software maker forecast revenue forthe year ending September 2014 below analysts' estimates onMonday. Raymond James, Stifel Nicolaus and JPMorgan cut their ratings on the stock on Tuesday.

Analysts at Stifel said the company did not clearlyarticulate a plan to cut expenses. Raymond James analysts said areturn to revenue growth could be delayed well into 2015 unlessthe company quickly improved sales execution.

** NEUROCRINE BIOSCIENCES INC, Monday close $16.70,down 28 pct premarket

The company said on Monday that a lower dose of itsexperimental drug to treat a rare movement disorder did not meetthe main goal of a mid-stage clinical study. Cowen and Co cut its price target on the stock to $19 from $20while MKM Partners cut its target to $13.50 from $17.00 andOppenheimer to $15 from $19.

** MARVELL TECHNOLOGY GROUP LTD, Monday close$12.57, up 3 pct premarket

J.P. Morgan Securities upgraded the chipmaker's stock to"overweight" from "neutral", saying the company's productdevelopment and execution over the last 18 months has spurredgrowth in its mobile/wireless and storage markets. Thebrokerage, expecting the company to control costs, raised itsprice target on the stock to $16 from $14.

** PALO ALTO NETWORKS INC, Monday close $46.84, up3.3 pct premarket

The security software maker on Monday reportedbetter-than-expected revenue for the fourth quarter, citing arise in demand for its appliances and contributions from morerecurring subscription and maintenance services. At least four brokerages raised their price targets on thestock.

** HD SUPPLY HOLDINGS INC, Monday close $24.74, down9.5 pct premarket

The construction products supplier reported a widerquarterly loss for the second quarter due to expenses associatedwith debt restructuring. The company also forecast fiscal 2013results below analysts' estimates.

** STARWOOD PROPERTY TRUST INC, Monday close$25.04, down 4 pct premarket

The company, which finances and manages commercial mortgageloans, said it was offering 25 million shares in an underwrittenpublic offering.

** L&L ENERGY INC, Monday close $2.89, up 15 pctafter market

The coal miner's first-quarter profit more than doubled asproduction was boosted by the acquisition of two mines in Chinain November. Production rose 54 percent to 228,000 tons in thequarter.

** FIVE BELOW INC, Monday close $41.04, up 14 pctafter market

The specialty value retailer reported better-than-expectedresults for the second quarter due to a 6.6 percent increase insame-store sales. The company also raised its full-year earningsand revenue forecast.

** PVH CORP, Monday close $132.11, down 4.4 pctafter market

The maker of Calvin Klein and Tommy Hilfiger clothes gave athird-quarter sales and profit forecast that was below analysts'estimates. The company characterized the global environment as"challenging".

** BLACKBERRY LTD, Monday close $11.53, down 4 pctpremarket

The Canadian company's biggest shareholder has approachedseveral large Canadian investment funds about forging a deal totake the smartphone maker private, but the proposal is still "anairy-fairy, 'what if' kind of thing," according to a source withdirect knowledge of the situation.

** GLAXOSMITHKLINE PLC, Monday close $50.46, down 1pct premarket

The threat of generic copies of the company's best-sellinglung drug Advair finally making it to the market in the UnitedStates hit confidence in the drugmaker.

** MICROSOFT CORP, Monday close $31.65, up 1 pctpremarket

At least three of the top 20 investors in the company want aturnaround expert to succeed Steve Ballmer as chief executive.They have urged the technology giant's board to consider FordMotor Co Chief Executive Alan Mulally and ComputerSciences Corp Chief Executive Mike Lawrie for the job,several sources familiar with the matter said.

** VODAFONE PLC , Monday close $33.34, down1.5 pct premarket

The company is facing pressure from Kabel Deutschland's largest shareholder to raise its 7.7 billion euro($10.1 billion) offer for Germany's largest cable company, twosources familiar with the situation told Reuters on Monday. Activist investor Paul E. Singer, founder of U.S. hedge fundElliott Asset Management, more than doubled his stake to 10.9percent on Sept. 6, Kabel Deutschland said on Monday two daysbefore shareholders have to decide whether to accept Vodafone'soffer.

** ADVANCED MICRO DEVICES INC, Monday close $3.69,up 2 pct premarket

The chipmaker, targeting new markets as personal computersales decline, unveiled chips designed to run slot machines,factory robots, airport signs, medical equipment and otherdevices. (Compiled by Varun Aggarwal; Editing by Kirti Pandey)

More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.